Pesticidal compositions and processes related thereto
US-9215870-B2 · Dec 22, 2015 · US
Compounds and pharmaceutical compositions for reducing CD95-mediated cell motility
US11905253B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11905253-B2 |
| Application number | US-201917049680-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 19, 2019 |
| Priority date | Apr 23, 2018 |
| Publication date | Feb 20, 2024 |
| Grant date | Feb 20, 2024 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates the field of reducing CD95-mediated cell motility in a subject, in particular for their use in the reduction of CD-95 mediated cancer cell motility, the reduction of CD95-mediated lymphocyte motility and/or B cell maturation, or the treatment of B-cell tumors, in a subject. The inventors identified a novel family of compounds having the ability to disrupt CD95/PLCγ1 interaction and to neutralize the CD95-mediated calcium signaling pathway and cell migration in human peripheral blood lymphocytes (PBLs) and Th17 cells. Thus, the present invention relates to compounds of formula (A) as defined in the present text, to a pharmaceutical composition comprising said compounds in a pharmaceutically acceptable medium and to the use of these compounds and compositions as medicament, in particular for their use in the reduction or treatment of the above-mentioned pathologies, and in particular in the treatment of cancers and autoimmune inflammatory disease such as systemic lupus erythematosus, inflammatory condition and Th17-mediated disease.
First claim
Opening claim text (preview).
The invention claimed is: 1. A compound comprising N-acylated-N-aminoethyl amino acids, selected from the group consisting of: Compound Structure Compound 1 Compound 2 Compound 3 Compound 4 Compound 5 Compound 6 Compound 7 Compound 8 Compound 9 Compound 10 Compound 11 Compound 12 Compound 13 Compound 14 Compound 15 Compound 16 Compound 17 Compound 18 Compound 19 Compound 20 Compound 21 Compound 22 Compound 23 Compound 24 Compound 25 Compound 26
Assignees
Inventors
Classifications
- C07D233/64Primary
with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
Drugs for immunological or allergic disorders · CPC title
- C07D207/337Primary
Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals · CPC title
Amides · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11905253B2 cover?
- The present invention relates the field of reducing CD95-mediated cell motility in a subject, in particular for their use in the reduction of CD-95 mediated cancer cell motility, the reduction of CD95-mediated lymphocyte motility and/or B cell maturation, or the treatment of B-cell tumors, in a subject. The inventors identified a novel family of compounds having the ability to disrupt CD95/PLCγ…
- Who is the assignee on this patent?
- Inst Nat Sante Rech Med, Univ Rennes, Centre Hospitalier Univ Bordeaux, and 3 more
- What technology area does this patent fall under?
- Primary CPC classification C07D233/64. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Feb 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).